Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sierecki

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine|August 8, 2019
Value of copeptin and the S-100b protein assay in ruling out the diagnosis of stroke-induced dizziness pattern in emergency departmentsN Deboevere, N Marjanovic, M Sierecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesY Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine|August 8, 2019
Value of copeptin and the S-100b protein assay in ruling out the diagnosis of stroke-induced dizziness pattern in emergency departmentsN Deboevere, N Marjanovic, M Sierecki, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesY Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Pageof 1